One doctor writes ten prescriptions a day. Another writes two hundred. Both might be doing honest work. But the second one is far more likely to get a call from a federal investigator.
Prescribing volume is one of the simplest numbers for regulators to pull from a database, and it is one of the fastest ways a telehealth clinic ends up under review. High-volume telehealth prescribing fraud cases almost always start with this same first step, a report that shows one prescriber writing far more scripts than everyone around them. This post breaks down exactly how volume turns into a red flag, what else investigators look for alongside it, and what you can do to keep your numbers from setting off alarms you never meant to trigger.
What Counts as High-Volume Telehealth Prescribing
There is no single number written in law that says "this many prescriptions equals fraud." Instead, investigators compare a prescriber's numbers to what is normal for their specialty, their state, and their patient type.
A few things tend to stand out on paper:
- Writing far more prescriptions per patient visit than peers in the same field.
- A big jump in prescription counts over a short stretch of time, like a few months.
- A large share of those prescriptions being for controlled substances instead of routine medication.
- Prescriptions going to patients spread across many states, all tied to one prescriber.
On its own, high volume is not proof of anything wrong. Some clinics see thousands of patients because they run a busy, well-organized service. But once volume gets flagged, it usually opens the door to a much closer look, which is why understanding the 2026 DEA telemedicine requirements matters just as much as watching your own numbers.
It also helps to think about volume the way an investigator does, as a ratio rather than a raw count. A prescriber who sees three hundred patients a month but only writes controlled substances for a small share of them looks very different from a prescriber who writes a controlled substance script at nearly every single visit. The second one draws attention faster, even with a smaller total patient count, because the ratio itself is the signal.
Specialty also changes what counts as normal. A pain management clinic will naturally write more controlled substance prescriptions than a general wellness clinic, and reviewers know that. The comparison is always against similar practices, not against every prescriber in the country lumped together.
Why High-Volume Telehealth Prescribing Fraud Raises DEA Red Flags
Regulators are not trying to punish busy clinics. They are trying to catch a specific pattern: prescribers who write large numbers of scripts with little or no real exam, little follow-up, and almost no denials.
That pattern shows up again and again in past enforcement cases. A prescriber who says yes to nearly every patient, who spends only a minute or two per visit, and who writes a controlled substance script almost every time, looks very different from a normal medical practice. Volume is the first thread investigators pull, because it is easy to measure and easy to compare against a whole database of other prescribers.
Among the clearest DEA prescribing red flags are a near 100 percent approval rate for medication requests, prescriptions written before any real conversation with the patient, and refill patterns that do not match how the drug is supposed to be used.
Common Telehealth Fraud Audit Triggers Beyond Volume Alone
Volume rarely acts alone. It is usually one piece of a bigger picture that adds up to a telehealth fraud audit trigger. Here are the pieces investigators tend to line up next to volume.
Short or Missing Patient Visits
If a visit lasts three minutes and ends in a controlled substance prescription, that gap between the length of the visit and the seriousness of the medication stands out.
One Prescriber, Many States
A single prescriber writing scripts for patients in dozens of states, often through the same marketing company or call center, is a pattern regulators have seen before in past fraud cases.
Templated or Copy-Paste Notes
When patient charts read almost word for word the same, it suggests the exam was not really individual to each patient.
Financial Ties to a Third Party
Some arrangements pay a prescriber based on how many scripts they write, or how many patients they see, instead of a flat rate. That kind of pay structure by itself can raise questions.
Patients Who Never Get a Physical Exam
For most controlled substances, the law expects at least one real evaluation before a prescription goes out, whether that happens in person or through a proper telehealth visit. Skipping that step entirely, or treating it as a formality, is one of the fastest ways to draw scrutiny.
None of these triggers work alone in most real cases. A reviewer might start with a volume report, then pull ten patient charts to see if the notes are individualized, then check how many of those patients live outside the prescriber's licensed states. Each answer either calms the concern or adds to it.
These triggers often connect to how a clinic is staffed and licensed across state lines. If you have not reviewed your setup lately, our guide on Cross-State Licensure & Interstate Practice Compliance for Telehealth Clinicians is a good next stop.
How Investigators Study Controlled Substance Prescribing Patterns
Federal and state investigators pull prescribing data from prescription drug monitoring programs, insurance claims, and pharmacy fill records. They are not reading files one at a time. They are running the numbers through software that flags anything unusual.
A few of the specific things that software looks for:
- A prescriber whose ratio of controlled substances to total prescriptions sits far above the norm for their specialty.
- Patients who fill prescriptions from the same telehealth prescriber but live hundreds of miles from any of that prescriber's licensed states.
- A spike in new patients right after a marketing push, paired with a spike in prescriptions.
- Multiple patients getting the exact same drug, dose, and quantity, over and over.
This kind of pattern matching is exactly why controlled substance prescribing patterns get so much attention in telehealth specifically. Prescribing in person naturally slows a prescriber down. Prescribing online can remove that friction, which is part of why the rules around controlled substance prescribing via telehealth are so detailed in the first place.
"
“Documentation is not just a record of what happened; it is a reflection of the clinical decision-making process and the care provided to the patient.”
— Dr. Robert M. Wah, Physician and Former President, American Medical Association (AMA)
Real Signs of Suspicious Telehealth Prescribing Activity
Some warning signs are obvious once you know to look for them. If any of these sound familiar in your own clinic, it is worth a closer look before a regulator takes one.
- Patients getting a prescription without ever speaking to a licensed prescriber directly.
- Visits that are scheduled and closed out in under five minutes, every time.
- A near-zero denial rate, where almost every patient who asks for a medication gets it.
- Prescribers who are licensed in only a few states but somehow have patients in twenty or more.
- Refill requests that get approved automatically, without any check-in.
None of these signs alone means a clinic is committing fraud. But stacked together, they describe exactly the kind of suspicious telehealth prescribing activity that shows up in real enforcement actions.
It is worth noting that patients themselves rarely complain when these signs are present. Getting a prescription quickly and easily feels like good service, not a warning sign, from the patient's side of the screen. That is part of what makes this kind of activity hard to catch early. The clinic often has to police its own patterns, because the people receiving the care have no reason to raise a flag.
Steps to Lower Your Telehealth Prescribing Audit Risk
You cannot control how busy your clinic gets, and you should not have to turn away real patients just to keep your numbers low. What you can control is how well your process holds up if someone ever looks closely at it.
Document Every Visit Like Someone Will Read It
Notes should reflect the actual conversation with that patient, not a copy of the last file. A few extra minutes per note can matter a lot later.
Track Your Own Numbers Before Anyone Else Does
Run your own reports on approval rates, visit length, and controlled substance ratios. If your numbers look unusual, you want to know why before a regulator asks you.
Watch Your Payment Structure
Pay prescribers a flat rate tied to time and quality of care, not a rate tied to the number of scripts written. That single change removes one of the biggest red flags investigators look for.
Keep Licensing Airtight
Every prescriber should hold an active license in every state where their patients are located, with no gaps.
Set Real Denial Standards
A clinic where prescribers sometimes say no, and can explain why, looks nothing like a script mill on paper.
For the full regulatory picture these steps sit inside, our DEA Telehealth Prescribing Rules: Complete 2026 Guide to the Ryan Haight Act walks through everything a telehealth clinic needs to stay on the right side of federal rules.
It also helps to check your practices against guidance straight from the DEA's Diversion Control Division, and to review how the HHS Office of Inspector General defines waste, fraud, and abuse in health care generally, since telehealth fraud waste and abuse cases often get built using those same standards.
Frequently Asked Questions
Does high volume alone prove fraud?
No. Volume is a starting point, not proof. Investigators look at volume alongside visit length, denial rates, and documentation before drawing any conclusion.
How do investigators find high-volume prescribers in the first place?
They pull data from prescription drug monitoring programs and pharmacy records, then compare each prescriber's numbers against others in the same specialty and location.
Can a clinic lower its risk without cutting patient numbers?
Yes. Better documentation, flat-rate pay structures, and honest denial rates all lower risk without turning away real patients.
What happens after a telehealth prescribing fraud review starts?
It usually starts with a records request. If the reviewer finds a pattern that concerns them, it can move into a formal audit or investigation, which is why clean records matter from day one.
Final Thoughts
High-volume telehealth prescribing fraud is not about being a busy clinic. It is about the gap between how many prescriptions go out and how much real care backs each one up. Close that gap with solid documentation, fair pay structures, and honest denial rates, and volume stops being something to fear.
If you want a full breakdown of the federal rules behind all of this, read our 2026 DEA telemedicine requirements guide next, or reach out to our team for a compliance check on your own prescribing patterns before a regulator asks for one.